908 Devices

MASS · NASDAQ

$11.51+$0.08 (+0.70%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $11.43

MASS analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $13.64 (+18.5% upside)

Low: $12.12
Now: $11.51
High: $14.70

Upgrades and downgrades

The latest rating actions, newest first

MASS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Canaccord Genuity	Sep 10, 2026	Initiates	Buy	$13.50	31%
Stifel	Aug 12, 2026	Maintains	Buy	$10.00 → $12.00	65%
Roth Capital	Aug 12, 2026	Maintains	Buy	$11.00 → $13.00	36%
Roth Capital	Jul 29, 2026	Initiates	Buy	$11.00	36%

The case for and against

Updated Nov 7, 2024

Bull case

908 Devices Inc. is positioned favorably due to heightened growth prospects in its Handheld segment, bolstered by the recent acquisition of RedWave, which is anticipated to contribute $11 million to FY24 revenue with a growth rate exceeding 20%. Improvements in product technology and operational efficiencies are expected to drive demand and lead to a resurgence in Desktop revenues, ultimately enhancing overall cash flow. The CEO's recent stock purchases indicate strong confidence in the company’s forward momentum, reinforcing the belief in 908 Devices' positive trajectory within its market sectors.

Bear case

908 Devices Inc faces several challenges that contribute to a negative financial outlook. Firstly, a potential slowdown in cell and gene therapy spending could negatively impact growth expectations, particularly if funding within the biotech sector declines or if bioprocessing growth does not meet investor expectations. Additionally, delays in reimbursement for Exosome tests and tightened research budgets in academic institutions pose further risks to revenue growth, which are compounded by currency fluctuations from international operations.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.